Published in Oncotarget on May 24, 2016
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun (2016) 0.86
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun (2017) 0.80
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell (2016) 0.78
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov (2017) 0.75
Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget (2016) 0.75
The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5. Oncotarget (2017) 0.75
Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015). Expert Opin Ther Pat (2016) 0.75
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8(+) T Cell Responses to Chronic Viral Infections and Cancer. Front Immunol (2017) 0.75
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget (2017) 0.75
PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr (2010) 108.52
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
Features and development of Coot. Acta Crystallogr D Biol Crystallogr (2010) 89.46
XDS. Acta Crystallogr D Biol Crystallogr (2010) 67.46
Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr (2005) 61.38
REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr (2011) 39.32
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
A hot spot of binding energy in a hormone-receptor interface. Science (1995) 10.41
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc (2007) 9.92
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov (2004) 7.84
Discovering high-affinity ligands for proteins: SAR by NMR. Science (1996) 7.10
The future of immune checkpoint therapy. Science (2015) 5.59
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr D Biol Crystallogr (2009) 4.90
Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry (2005) 3.16
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A (2008) 2.03
Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol (2014) 1.95
PDBsum additions. Nucleic Acids Res (2013) 1.94
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol (2015) 1.68
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
PD-1/PD-L1 inhibitors. Curr Opin Pharmacol (2015) 1.53
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry (2001) 1.30
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure (2015) 1.27
Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem (2013) 1.27
A dimeric structure of PD-L1: functional units or evolutionary relics? Protein Cell (2010) 1.11
Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. J Am Chem Soc (2005) 0.96
Robust NMR screening for lead compounds using tryptophan-containing proteins. J Am Chem Soc (2009) 0.95
An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. J Med Chem (2007) 0.94
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew Chem Int Ed Engl (2014) 0.91